Affymetrix tech to be used in new gene study

India's Avesthagen has inked a deal to use Affymetrix's microarray technology in a genetic study involving 60,000 Parsi. The Avestagenome Project is studying the genetic foundation behind longevity. Almost a third of the Parsi population lives beyond the age of 60, compared to seven percent of the country's entire population.

- see this release
- read the story in the San Jose Business Journal

Related Articles:
Affymetrix to acquire ParAllele in $120M deal. Report
Longevity gene may be key to living past 100. Report
Biotechs pursue anti-aging treatments. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.